On Apr. 9, 2020, BioSig Technologies announced that an article titled “The IMPDH inhibitor merimepodib suppresses SARS-COV-2 replications” was published on bioRxiv. The article was the first public disclosure of pre-clinical data generated under contract with Galveston National Laboratory at The University of Texas Medical Branch.

Vicromax(tm), a broad-spectrum anti-viral candidate, demonstrated strong activity against COVID-19 in cell cultures in lab and pre-clinical testing has begun. The Company intends to pursue development of this agent for the treatment of COVID-19 through FDA-approved clinical trials in Q2 2020.